Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria

Allergologia et Immunopathologia

Volumn 43, Issue 2, 2015, Pages 168-173

  Silva, P M ^a   Costa, A C ^a   Mendes, A ^a   Barbosa, M P ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Anti IgE; Chronic spontaneous urticaria; Omalizumab

Indexed keywords

CETIRIZINE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; OMALIZUMAB; PREDNISOLONE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; ASSESSMENT OF HUMANS; CHRONIC SPONTANEOUS URTICARIA; CHRONIC URTICARIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA ACTIVITY SCORE; CHRONIC DISEASE; DRUG RESISTANCE; IMMUNOLOGY; RECURRENT DISEASE; TIME; URTICARIA;

ADULT; CHRONIC DISEASE; DRUG RESISTANCE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOGLOBULIN E; MALE; OMALIZUMAB; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; URTICARIA;

EID: 84926256801     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2013.11.007     Document Type: Article

References (17)

1. 2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009, 64:1417-1426.
2. Mlynek A., Magerl M., Hanna M., Lhachimi S., Baiardini I., Canonica G.W., et al. The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy 2009, 64:927-936.
3. Konstantinou G.N., Asero R., Ferrer M., Knol E.F., Maurer M., Raap U., et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy 2013, 68:27-36.
4. 2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009, 64:1427-1443.
5. Maurer M., Altrichter S., Bieber T., Biedermann T., Bräutigam M., Seyfried S., et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011, 128:202-209.
6. Spector S.L., Tan R.A. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007, 99:190-193.
7. Saini S., Rosen K.E., Hsieh H., Wong D.A., Conner E., Kaplan A., et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011, 128:567-573.
8. Maurer M., Rosen K., Hsieh H.J., Saini S., Grattan C., Gimenez-Arnau A., et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013, 368:924-935.
9. Kaplan A., Ledford D., Ashby M., Canvin J., Zazalli J., Conner E., et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticarial despite standard combination therapy. J Allergy Clin Immunol 2013, 132:101-109.
10. Mynek A., Zalewska-Janowska A., Martus P., Staubach P., Zuberbier T., Maurer M. How to assess disease activity in patients with chronic urticaria?. Allergy 2008, 63:777-780.
11. Groffik A., Mitzel-Kaoukhov H., Magerl M., Maurer M., Staubach P. Omalizumab - an effective and safe treatment of therapy resistant chronic spontaneous urticaria. Allergy 2011, 66:303-305.
12. Metz M., Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol 2012, 12:406-411.
13. Song C.H., Stern S., Giruparajah M., Berlin N., Sussman G.L. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol 2013, 110:113-117.
14. Beck L.A., Marcotte G.V., MacGlashan D., Togias A., Saini S. Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function. J Allergy Clin Immunol 2004, 114:527-530.
15. Oliver J.M., Tarleton C.A., Gilmartin L., Archibeque T., Qualls C.R., Diehl L., et al. Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol 2010, 151:275-284.
16. Romano C., Sellitto A., De Fanis U., Esposito G., Arbo P., Giunta R., et al. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria. Ann Allergy Asthma Immunol 2010, 104:95-97.
17. Ferrer M., Gamboa P., Sanz M.L., Goikoetxea M.J., Cabrera-Freitag P., Javaloyes G., et al. Omalizumab is effective in nonautoimmune urticaria. J Allergy Clin Immunol 2011, 127:1300-1302.